ReviewFuture medicinal chemistry2025
The current landscape of quinazoline derivatives with
Review in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The current landscape of quinazoline derivatives withFuture medicinal chemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the development of new technology, cancer has already transformed from a catastrophic disease to a treatable and sometimes curable disease. Chemotherapeutics is critical for cancer therapy, but multidrug resistance and severe side effects often lead to treatment failure, creating an urgent demand to develop innovative and efficient therapeutic interventions. Quinazoline hybrids could arrest the cell cycle, induce apoptosis, inhibit angiogenesis, and disrupt cell migration. Moreover, several quinazoline hybrids, exemplified by Fruquintinib (quinazoline-benzofuran hybrid) and Barasertib (quinazoline-pyrazole hybrid), have already been applied in clinics for cancer therapy, indicating that the rational design of quinazoline hybrids may provide valuable chemotherapeutics for cancer therapy. This review outlines the current scenario of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.